Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) and (e) OnJanuary 10, 2022 ,Foghorn Therapeutics Inc. (the "Company") entered into a transition agreement withCarl Decicco (the "Transition Agreement"). Under the Transition Agreement,Dr. Decicco will step down from his position as Chief Scientific Officer of the Company effective as ofJanuary 10, 2022 , will serve as Special Advisor to the Company's newly appointed Chief Scientific Officer throughJanuary 31, 2022 and will retire from the Company onJanuary 31, 2022 (the "Separation Date").Dr. Decicco will continue to receive his current base salary through the Separation Date and will be eligible to receive an annual bonus based on the achievement of the pre-established performance objectives in respect of fiscal year 2021. Under the Transition Agreement, any vested stock options held byDr. Decicco as of the Separation Date will remain exercisable untilJuly 5, 2022 . On this same date, the Company announced thatSteven Bellon , PhD. had been appointed to serve as the Company's Chief Scientific Officer, effective as ofJanuary 10, 2022 .Dr. Bellon joinedFoghorn Therapeutics in 2016 as head of drug discovery, bringing more than 20 years of drug discovery experience from multiple drug classes. Prior to joining Foghorn,Mr. Bellon was executive director and head of structural biology, and lead discovery and project management atConstellation Pharmaceuticals . Prior to his work at Constellation, he held positions of increasing responsibility atAmgen and Vertex Pharmaceuticals.Dr. Bellon received a Ph.D. in physical chemistry fromMIT under the direction ofStephen Lippard and then completed postdoctoral training atYale University withThomas Steitz , Nobel Laureate, funded by aDamon Runyon fellowship. The foregoing description of the Transition Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement, which agreement will be filed as an exhibit to the Company's next Form 10-K.
© Edgar Online, source